AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
VivoPower Soars 13.33% on $100M Ripple, XRP Investment
Generated by AI AgentAinvest Pre-Market Radar
Monday, Aug 11, 2025 6:35 am ET1min read
Aime SummaryOn August 11, 2025, VivoPower's shares rose by 13.33% in pre-market trading, marking a significant surge in investor interest.
VivoPower, a Nasdaq-listed solar firm, announced a $100 million plan to purchase
shares and tokens, becoming the first U.S. public company to offer dual exposure to Ripple equity and XRP. This strategic move aims to optimize XRP yield and reduce acquisition costs by 86% through direct token purchases and private share acquisitions from existing Ripple shareholders.The company's executive chairman and CEO, Kevin Chin, highlighted that the combined purchase of Ripple shares and XRP tokens would help maximize yield while minimizing the weighted average cost of XRP acquired. Independent audits of Ripple holdings will be conducted quarterly, with BitGo managing custody and Nasdaq Private Market facilitating the private share transactions.
VivoPower's decision to allocate a significant portion of capital to Ripple assets demonstrates a strong conviction in the company’s long-term prospects and underscores a strategic shift in VivoPower’s business model. This aligns the firm with the evolving digital asset landscape and highlights the increasing convergence between traditional equities and blockchain-based investments.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Dakota Gold DC shares plummeted 6.90% as mining stocks selloff follows sharp gold silver price declines
Dec.30 2025
Integra Resources shares plunge 9.58% on Dec. 30 2025 as project delays regulatory uncertainties spook investors
Dec.30 2025
AXT shares fell 5.07% in pre-market trading on Dec. 30 2025 amid sector pressures and speculative positioning adjustments.
Dec.30 2025
Autozi Internet shares surged 8.76% on strategic AI pivot and regulatory progress
Dec.30 2025
ProKidney shares plunged 13.04% due to regulatory scrutiny and operational concerns
Dec.30 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet